Conflict of interest statement: Disclosure: Dr. Findling receives or has 
received research support, served as a consultant for and/or served on the 
speakers’ bureau for Abbott, Addrenex, AstraZeneca, Biovail, Bristol-Myers 
Squibb, Forest, GlaxoSmithKline, Johnson and Johnson, KemPharm, Eli Lilly and 
Company, Lundbeck, Neuropharm, Novartis, Organon, Otsuka, Pfizer, 
Sanofi-Aventis, Sepracore, Shire, Solvay, Supernus Pharmaceuticals, Validus, and 
Wyeth. Dr. Frazier receives research funding from or participates in clinical 
trials with Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Johnson and Johnson, 
Neuropharm, Otsuka America Pharmaceutical, and Pfizer. Dr. Hamer, in the past 
three years, received or has receives research support, served as a consultant 
for and served on a data safety monitoring board (DSMB) / internal displacement 
monitoring centre (IDMC) for Acadia, Allergan, Alpharma, AstraZeneca, Cenerx, 
Corcept, EnabledMD, Epix, Johnson and Johnson, Novartis, Pepper-Hamilton, 
Pfizer, SAS Institute, Schwartz, Solvay, Sanofi-Aventis, Takeda, Winston-Strawn 
(a lawsuit involving Forest, Lundbeck, Sun, Caraco), and Wyeth. He and/or his 
wife own stock in Bristol-Myers Squibb, Amgen, Eli Lilly and Company, Genentech, 
Proctor and Gamble, and Sepracor. His wife is retired from Bristol-Myers Squibb. 
Dr. Liberman serves on the advisory board of Bioline, GlaxoSmithKline, 
Intracellular Therapies, Eli Lilly and Company, Psychogenics, and Wyeth. He does 
not receive financial compensation or salary support for his participating as an 
advisor, except for Intracellular Therapies. He receives grant support from 
Allon, Forest Labs, Merck, and Pfizer. He holds a patent from Repligen. Dr. 
Sikick receives research funding or participates in clinical trials with 
Janssen, Pfizer, Bristol-Myers Squibb, Neuropharm, Curemark, and Seaside 
Pharmaceuticals. She has receives software for a computer intervention in 
schizophrenia from Posit Science. In the past, Dr. Sikich received research 
funding from Eli Lilly and Company, Janssen, Pfizer, Otsuka, and AstraZeneca. 
She has served as a consultant for Sanofi Aventis and ABT Associates. Drs. 
Johnson, McClellan, Vitiello, McNamara, Hlastala, and Maloney, and Ms. Ritz, Ms. 
Lingler, Ms. Pierson, Ms. Puglia, Ms. Michael Kaufman, and Ms. Noyes report no 
biomedical financial interests or potential conflicts of interest.